{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-028345","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.046913+00:00","generated_at":"2026-05-26T02:25:37.013027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tango Therapeutics reports Q4 2024 net loss of $37.7M; cash runway into 3Q 2026","bullets":["Net loss of $37.7M for Q4 2024 ($0.35 per share) vs $30.8M loss in Q4 2023; full year net loss $130.3M ($1.19 per share).","Cash and marketable securities $257.9M as of Dec 31, 2024; expected to fund operations into 3Q 2026.","TNG462 granted FDA Orphan Drug Designation for pancreatic cancer; Phase 1/2 data update expected in 2025.","IND for TNG456 cleared; Phase 1/2 enrollment expected 1H 2025; clinical collaboration with Lilly for abemaciclib combination.","TNG260 proof-of-mechanism established; dose expansion ongoing in lung cancer; clinical update expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-028345","json":"https://secwatch.observer/filing/0000950170-25-028345.json","markdown":"https://secwatch.observer/filing/0000950170-25-028345.md","text":"https://secwatch.observer/filing/0000950170-25-028345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025028345/0000950170-25-028345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025028345/tngx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:25:37.013027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}